Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Ghamande SA, Silverman MH, Huh W, Behbakht K, Ball G, Cuasay L, Würtz SO, Brunner N, Gold MA. Ghamande SA, et al. Among authors: behbakht k. Gynecol Oncol. 2008 Oct;111(1):89-94. doi: 10.1016/j.ygyno.2008.06.028. Epub 2008 Aug 28. Gynecol Oncol. 2008. PMID: 18760451 Clinical Trial.
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Behbakht K, et al. Gynecol Oncol. 2011 Oct;123(1):19-26. doi: 10.1016/j.ygyno.2011.06.022. Epub 2011 Jul 12. Gynecol Oncol. 2011. PMID: 21752435 Free PMC article. Clinical Trial.
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
Alvarez RD, Sill MW, Davidson SA, Muller CY, Bender DP, DeBernardo RL, Behbakht K, Huh WK. Alvarez RD, et al. Among authors: behbakht k. Gynecol Oncol. 2014 Jun;133(3):433-8. doi: 10.1016/j.ygyno.2014.03.571. Epub 2014 Apr 4. Gynecol Oncol. 2014. PMID: 24708919 Free PMC article. Clinical Trial.
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
Zighelboim I, Ali S, Lankes HA, Backes F, Moore K, Mutch D, Robison K, Behbakht K, Waggoner S, Ghebre RG, Pearl M, Ramirez NC, Goodfellow P. Zighelboim I, et al. Among authors: behbakht k. Gynecol Oncol. 2015 Sep;138(3):614-9. doi: 10.1016/j.ygyno.2015.06.038. Epub 2015 Jul 3. Gynecol Oncol. 2015. PMID: 26144601 Free PMC article.
106 results